ATE555116T1 - Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie - Google Patents

Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie

Info

Publication number
ATE555116T1
ATE555116T1 AT09714617T AT09714617T ATE555116T1 AT E555116 T1 ATE555116 T1 AT E555116T1 AT 09714617 T AT09714617 T AT 09714617T AT 09714617 T AT09714617 T AT 09714617T AT E555116 T1 ATE555116 T1 AT E555116T1
Authority
AT
Austria
Prior art keywords
treatment
ahcy
hyperhomocysteinemia
hydrolase inhibitors
inhibitors
Prior art date
Application number
AT09714617T
Other languages
English (en)
Inventor
Robert Garbaccio
Antonella Converso
Mark Fraley
Timothy Hartingh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE555116T1 publication Critical patent/ATE555116T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AT09714617T 2008-02-26 2009-02-18 Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie ATE555116T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6721008P 2008-02-26 2008-02-26
PCT/US2009/034344 WO2009108546A1 (en) 2008-02-26 2009-02-18 Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia

Publications (1)

Publication Number Publication Date
ATE555116T1 true ATE555116T1 (de) 2012-05-15

Family

ID=41016437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09714617T ATE555116T1 (de) 2008-02-26 2009-02-18 Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie

Country Status (4)

Country Link
US (1) US8329697B2 (de)
EP (1) EP2257161B1 (de)
AT (1) ATE555116T1 (de)
WO (1) WO2009108546A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329697B2 (en) * 2008-02-26 2012-12-11 Merck Sharp & Dohme Corp. Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors
EP2486925A4 (de) * 2009-10-09 2014-03-19 Mitsubishi Tanabe Pharma Corp Therapeutikum für ischämischen schlaganfall
JP5641664B2 (ja) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap イミダゾ[1,2−b]ピリダジン誘導体およびPDE10阻害剤としてのそれらの使用
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2017123058A1 (en) 2016-01-14 2017-07-20 Handok Inc. Compounds antagonizing a3 adenosine receptor, method for preparing them, and medical-use thereof
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN116840197A (zh) * 2022-03-23 2023-10-03 中国科学院苏州生物医学工程技术研究所 一种2’-o-甲基转移酶活性检测方法、试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507294A (en) * 1982-03-08 1985-03-26 Schering Corp. Imidazo[1,2-a]pyrazines
US5521162A (en) * 1987-08-26 1996-05-28 Merrell Pharmaceuticals Inc. Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions
US7208495B2 (en) * 2001-07-05 2007-04-24 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US8329697B2 (en) * 2008-02-26 2012-12-11 Merck Sharp & Dohme Corp. Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors

Also Published As

Publication number Publication date
US20100305135A1 (en) 2010-12-02
US8329697B2 (en) 2012-12-11
EP2257161B1 (de) 2012-04-25
EP2257161A1 (de) 2010-12-08
WO2009108546A1 (en) 2009-09-03
EP2257161A4 (de) 2011-03-16

Similar Documents

Publication Publication Date Title
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201070247A1 (ru) Ингибиторы протеасом
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201270575A1 (ru) Соединения
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
IN2014KN02601A (de)
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EP2582676A4 (de) Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren